TY - JOUR AU - Lipton, R. B. AU - Bigal, M. E. AU - Diamond, M. AU - Freitag, F. AU - Reed, M. L. AU - Stewart, W. F. PY - 2007 DA - 2007// TI - Migraine prevalence, disease burden, and the need for preventive therapy JO - Neurology. VL - 68 UR - https://doi.org/10.1212/01.wnl.0000252808.97649.21 DO - 10.1212/01.wnl.0000252808.97649.21 ID - Lipton2007 ER - TY - JOUR PY - 2018 DA - 2018// TI - The International Classification of Headache Disorders, 3rd edition JO - Cephalalgia VL - 38 UR - https://doi.org/10.1177/0333102417738202 DO - 10.1177/0333102417738202 ID - ref2 ER - TY - JOUR PY - 2018 DA - 2018// TI - Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 JO - Lancet VL - 392 UR - https://doi.org/10.1016/S0140-6736(18)32279-7 DO - 10.1016/S0140-6736(18)32279-7 ID - ref3 ER - TY - JOUR AU - Steiner, T. J. AU - Stovner, L. J. AU - Vos, T. AU - Jensen, R. AU - Katsarava, Z. PY - 2018 DA - 2018// TI - Migraine is first cause of disability in under 50s: will health politicians now take notice? JO - J Headache Pain VL - 19 UR - https://doi.org/10.1186/s10194-018-0846-2 DO - 10.1186/s10194-018-0846-2 ID - Steiner2018 ER - TY - JOUR AU - Silberstein, S. D. AU - Holland, S. AU - Freitag, F. AU - Dodick, D. W. AU - Argoff, C. AU - Ashman, E. PY - 2012 DA - 2012// TI - Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards Subcommittee of the American Academy of neurology and the American headache society JO - Neurology. VL - 78 UR - https://doi.org/10.1212/WNL.0b013e3182535d20 DO - 10.1212/WNL.0b013e3182535d20 ID - Silberstein2012 ER - TY - JOUR AU - Martelletti, P. PY - 2015 DA - 2015// TI - The therapeutic armamentarium in migraine is quite elderly JO - Expert Opin Drug Metab Toxicol VL - 11 UR - https://doi.org/10.1517/17425255.2015.982089 DO - 10.1517/17425255.2015.982089 ID - Martelletti2015 ER - TY - JOUR AU - Luykx, J. AU - Mason, M. AU - Ferrari, M. D. AU - Carpay, J. PY - 2009 DA - 2009// TI - Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine JO - Clin Pharmacol Ther VL - 85 UR - https://doi.org/10.1038/clpt.2008.203 DO - 10.1038/clpt.2008.203 ID - Luykx2009 ER - TY - JOUR AU - Berger, A. AU - Bloudek, L. M. AU - Varon, S. F. AU - Oster, G. PY - 2012 DA - 2012// TI - Adherence with migraine prophylaxis in clinical practice JO - Pain Pract VL - 12 UR - https://doi.org/10.1111/j.1533-2500.2012.00530.x DO - 10.1111/j.1533-2500.2012.00530.x ID - Berger2012 ER - TY - JOUR AU - Aurora, S. K. AU - Dodick, D. W. AU - Turkel, C. C. AU - DeGryse, R. E. AU - Silberstein, S. D. AU - Lipton, R. B. PY - 2010 DA - 2010// TI - OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial JO - Cephalalgia. VL - 30 UR - https://doi.org/10.1177/0333102410364676 DO - 10.1177/0333102410364676 ID - Aurora2010 ER - TY - JOUR AU - Diener, H. C. AU - Dodick, D. W. AU - Aurora, S. K. AU - Turkel, C. C. AU - DeGryse, R. E. AU - Lipton, R. B. PY - 2010 DA - 2010// TI - OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial JO - Cephalalgia. VL - 30 UR - https://doi.org/10.1177/0333102410364677 DO - 10.1177/0333102410364677 ID - Diener2010 ER - TY - JOUR AU - Martelletti, P. PY - 2017 DA - 2017// TI - The application of CGRP(r) monoclonal antibodies in migraine Spectrum: needs and priorities JO - BioDrugs. VL - 31 UR - https://doi.org/10.1007/s40259-017-0251-4 DO - 10.1007/s40259-017-0251-4 ID - Martelletti2017 ER - TY - JOUR AU - Tiseo, C. AU - Ornello, R. AU - Pistoia, F. AU - Sacco, S. PY - 2019 DA - 2019// TI - How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice JO - J Headache Pain VL - 20 UR - https://doi.org/10.1186/s10194-019-1000-5 DO - 10.1186/s10194-019-1000-5 ID - Tiseo2019 ER - TY - JOUR AU - Martelletti, P. AU - Edvinsson, L. AU - Ashina, M. PY - 2019 DA - 2019// TI - Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs) JO - J Headache Pain VL - 20 UR - https://doi.org/10.1186/s10194-019-1009-9 DO - 10.1186/s10194-019-1009-9 ID - Martelletti2019 ER - TY - JOUR AU - Sacco, S. AU - Bendtsen, L. AU - Ashina, M. AU - Reuter, U. AU - Terwindt, G. AU - Mitsikostas, D. D. PY - 2019 DA - 2019// TI - European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention JO - J Headache Pain VL - 20 UR - https://doi.org/10.1186/s10194-018-0955-y DO - 10.1186/s10194-018-0955-y ID - Sacco2019 ER - TY - JOUR AU - Martelletti, P. PY - 2019 DA - 2019// TI - Erenumab is effective in reducing migraine frequency and improving physical functioning JO - BMJ Evid Based Med VL - 24 UR - https://doi.org/10.1136/bmjebm-2018-110937 DO - 10.1136/bmjebm-2018-110937 ID - Martelletti2019 ER - TY - BOOK PY - 2019 DA - 2019// TI - Aimovig, INN-erenumab ID - ref16 ER - TY - JOUR AU - Tepper, S. AU - Ashina, M. AU - Reuter, U. AU - Brandes, J. L. AU - Doležil, D. AU - Silberstein, S. PY - 2017 DA - 2017// TI - Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial JO - Lancet Neurol VL - 16 UR - https://doi.org/10.1016/S1474-4422(17)30083-2 DO - 10.1016/S1474-4422(17)30083-2 ID - Tepper2017 ER - TY - JOUR AU - Goadsby, P. J. AU - Reuter, U. AU - Hallström, Y. AU - Broessner, G. AU - Bonner, J. H. AU - Zhang, F. PY - 2017 DA - 2017// TI - A controlled trial of Erenumab for episodic migraine JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1705848 DO - 10.1056/NEJMoa1705848 ID - Goadsby2017 ER - TY - JOUR AU - Reuter, U. AU - Goadsby, P. J. AU - Lanteri-Minet, M. AU - Wen, S. AU - Hours-Zesiger, P. AU - Ferrari, M. D. PY - 2018 DA - 2018// TI - Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study JO - Lancet. VL - 392 UR - https://doi.org/10.1016/s0140-6736(18)32534-0 DO - 10.1016/s0140-6736(18)32534-0 ID - Reuter2018 ER - TY - JOUR AU - Ornello, R. AU - Tiseo, C. AU - Frattale, I. AU - Perrotta, G. AU - Marini, C. AU - Pistoia, F. PY - 2019 DA - 2019// TI - The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal JO - J Headache Pain VL - 20 UR - https://doi.org/10.1186/s10194-019-1054-4 DO - 10.1186/s10194-019-1054-4 ID - Ornello2019 ER - TY - CHAP AU - Robbins, L. AU - Phenicie, B. PY - 2018 DA - 2018// TI - Early data on the 1st migraine-inhibiting CGRP BT - Practical Pain Management ID - Robbins2018 ER - TY - JOUR AU - Barbanti, P. AU - Aurilia, C. AU - Egeo, G. AU - Fofi, L. PY - 2019 DA - 2019// TI - Erenumab: from scientific evidence to clinical practice-the first Italian real-life data JO - Neurol Sci VL - 40 UR - https://doi.org/10.1007/s10072-019-03839-x DO - 10.1007/s10072-019-03839-x ID - Barbanti2019 ER - TY - BOOK PY - 2019 DA - 2019// TI - Popolazione residente al 1° gennaio 2019 - Abruzzo ID - ref23 ER - TY - JOUR AU - Steiner, T. J. AU - Göbel, H. AU - Jensen, R. AU - Lampl, C. AU - Paemeleire, K. AU - Linde, M. PY - 2019 DA - 2019// TI - Headache service quality: the role of specialized headache centres within structured headache services, and suggested standards and criteria as centres of excellence JO - J Headache Pain VL - 20 UR - https://doi.org/10.1186/s10194-019-0970-7 DO - 10.1186/s10194-019-0970-7 ID - Steiner2019 ER - TY - JOUR PY - 2019 DA - 2019// TI - The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice JO - Headache VL - 59 UR - https://doi.org/10.1111/head.13456 DO - 10.1111/head.13456 ID - ref25 ER - TY - JOUR AU - Dodick, D. W. AU - Ashina, M. AU - Brandes, J. L. AU - Kudrow, D. AU - Lanteri-Minet, M. AU - Osipova, V. PY - 2018 DA - 2018// TI - ARISE: a phase 3 randomized trial of erenumab for episodic migraine JO - Cephalalgia. VL - 38 UR - https://doi.org/10.1177/0333102418759786 DO - 10.1177/0333102418759786 ID - Dodick2018 ER - TY - JOUR AU - Torres-Ferrus, M. AU - Quintana, M. AU - Fernandez-Morales, J. AU - Alvarez-Sabin, J. AU - Pozo-Rosich, P. PY - 2017 DA - 2017// TI - When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month JO - Cephalalgia. VL - 37 UR - https://doi.org/10.1177/0333102416636055 DO - 10.1177/0333102416636055 ID - Torres-Ferrus2017 ER - TY - JOUR AU - Dresler, T. AU - Caratozzolo, S. AU - Guldolf, K. AU - Huhn, J. I. AU - Loiacono, C. AU - Niiberg-Pikksööt, T. PY - 2019 DA - 2019// TI - Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications JO - J Headache Pain VL - 20 UR - https://doi.org/10.1186/s10194-019-0988-x DO - 10.1186/s10194-019-0988-x ID - Dresler2019 ER - TY - JOUR AU - Aguggia, M. PY - 2012 DA - 2012// TI - Allodynia and migraine JO - Neurol Sci VL - 33 UR - https://doi.org/10.1007/s10072-012-1034-9 DO - 10.1007/s10072-012-1034-9 ID - Aguggia2012 ER - TY - JOUR AU - Edvinsson, L. AU - Ho, T. W. PY - 2010 DA - 2010// TI - CGRP receptor antagonism and migraine JO - Neurotherapeutics. VL - 7 UR - https://doi.org/10.1016/j.nurt.2010.02.004 DO - 10.1016/j.nurt.2010.02.004 ID - Edvinsson2010 ER - TY - JOUR AU - Sun, R. Q. AU - Lawand, N. B. AU - Willis, W. D. PY - 2003 DA - 2003// TI - The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin JO - Pain. VL - 104 UR - https://doi.org/10.1016/s0304-3959(03)00008-3 DO - 10.1016/s0304-3959(03)00008-3 ID - Sun2003 ER - TY - JOUR AU - Lovati, C. AU - D'Amico, D. AU - Rosa, S. AU - Suardelli, M. AU - Mailland, E. AU - Bertora, P. PY - 2007 DA - 2007// TI - Allodynia in different forms of migraine JO - Neurol Sci VL - 28 UR - https://doi.org/10.1007/s10072-007-0781-5 DO - 10.1007/s10072-007-0781-5 ID - Lovati2007 ER - TY - JOUR AU - Pijpers, J. A. AU - Kies, D. A. AU - Louter, M. A. AU - Zwet, E. W. AU - Ferrari, M. D. AU - Terwindt, G. M. PY - 2019 DA - 2019// TI - Acute withdrawal and botulinum toxin a in chronic migraine with medication overuse: a double-blind randomized controlled trial JO - Brain. VL - 142 UR - https://doi.org/10.1093/brain/awz052 DO - 10.1093/brain/awz052 ID - Pijpers2019 ER - TY - JOUR AU - Tepper, S. J. AU - Diener, H. C. AU - Ashina, M. AU - Brandes, J. L. AU - Friedman, D. I. AU - Reuter, U. PY - 2019 DA - 2019// TI - Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial JO - Neurology. VL - 92 UR - https://doi.org/10.1212/WNL.0000000000007497 DO - 10.1212/WNL.0000000000007497 ID - Tepper2019 ER - TY - JOUR AU - Ashina, M. AU - Goadsby, P. J. AU - Reuter, U. AU - Silberstein, S. AU - Dodick, D. AU - Rippon, G. A. PY - 2019 DA - 2019// TI - Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine JO - Cephalalgia. VL - 39 UR - https://doi.org/10.1177/0333102419854082 DO - 10.1177/0333102419854082 ID - Ashina2019 ER - TY - JOUR AU - Ashina, M. AU - Kudrow, D. AU - Reuter, U. AU - Dolezil, D. AU - Silberstein, S. AU - Tepper, S. J. PY - 2019 DA - 2019// TI - Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions JO - Cephalalgia. VL - 39 UR - https://doi.org/10.1177/0333102419888222 DO - 10.1177/0333102419888222 ID - Ashina2019 ER -